Europe and Korea to Share Confidential COVID-19 Information
The European Medicines Agency (EMA) and the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) have announced an agreement that will enable the parties to share confidential information on COVID-19 medicines.
The European Medicines Agency (EMA) and the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) have announced an agreement that will enable the parties to share confidential information on COVID-19 medicines.
According to a June 30, 2020 press release, the agreement is an ad-hoc arrangement, exclusively focused on medicines intended for the treatment, diagnosis, or prevention of COVID-19. This latest arrangement works harmoniously with EMA’s other confidential agreements with other countries and organizations.
The strategic coordination between global regulators will be managed by the International Coalition of Medicines Regulatory Authorities (ICMRA), which is chaired by EMA. To enable various regulatory authorities to discuss related COVID-19 work, ICMRA is holding bi-weekly meetings in the hope that medicine and vaccine development will be expedited.
Source: EMA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
